Zhu D, Lv M, Bai Y, Wu J, He P. Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in Beijing: A modeling analysis. Vaccine. 2022 Jan 19:S0264-410X(22)00024-X
Methods: A decision tree was developed to compare 1-year outcomes of TIV vs. QIV in three risk groups: school children, elderly adults, and HCWs. The outcome was incremental cost per quality-adjusted life-year (QALY). Probabilistic sensitivity analyses and scenario analyses were developed to assess the robustness of the results.
Results: From the perspective of society, this study found that the introduction of QIVs can be cost-effective for any and all targeted groups with a willingness-to-pay threshold of 3-fold GDP per capita. Among all programs, program H (all school children, elderly adults, and HCWs received the QIV) showed a 79% probability of being cost-effective with an incremental cost-effectiveness ratio (ICER) of 13,580 (95% CI: 13,294, 13,867) US$/QALY and was the preferred option in the base case scenario.
Conclusion: The introduction of QIVs to school children, elderly adults, or HCWs is likely to be cost-effective, either separately or collectively. The introduction of QIV to school children, elderly adults, and health care workers simultaneously showed the highest probability of being cost-effective and was the preferred option.
- All-trans retinoic acid increases the pathogenicity of the H9N2 influenza virus in mice 2 days ago
- Genetic and Antigenic Characterization of an Expanding H3 Influenza A Virus Clade in U.S. Swine Visualized by Nextstrain 2 days ago
- A chimeric thermostable M2e and H3 stalk-based universal influenza A virus vaccine 2 days ago
- Epidemiological and virological surveillance of influenza viruses in China during 2020-2021 2 days ago
- Infection of Human Precision-Cut Lung Slices with the Influenza Virus 2 days ago